Nammi Therapeutics

Nammi Therapeutics is an immunotherapy company developing first-class cancer treatment products. It is developing platforms and products that selectively activate anti-tumor immunity in the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi hopes to improve safety and enhance the ability to combine multiple immune modulators. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver immune-modulating prodrugs (IMP) using its Nammisome technology. Multiple Nammisome clinical candidates have been selected for development.